Razelle Kurzrock: Our newest DART study
Razelle Kurzrock shared a post by Journal for ImmunoTherapy of Cancer, on X, adding:
“Our newest DART study. Nivolumab/Ipilimumab Adrenocortical is a tough cancer. 5 of 21 patients with iresponses/benefit for over one year; one ongoing for five years.”
Quoting Journal for ImmunoTherapy of Cancer‘s post:
“New JITC short report: Phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors (DART) SWOG S1609: adrenocortical carcinoma cohort.”
Phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors (DART) SWOG S1609: adrenocortical carcinoma cohort
Autors: Sandip P Patel, Megan Othus, Young Kwang Chae, Tridu Huynh, Benjamin Tan, Timothy Kuzel, Christine McLeod, Gabby Lopez, Helen X Chen, Elad Sharon, Howard Streicher, Christopher W Ryan, Charles Blanke and Razelle Kurzrock
Source: Razelle Kurzrock/X and Journal for ImmunoTherapy of Cancer/X
Dr. Razelle Kurzrock is the Chief Medical Officer at ACT Genomics, Senior Deputy Director at the HKSH Cancer Centre, and Senior Advisor at CureScience.
She is also a Professor of Medicine at the University of California, San Diego (UCSD) and the Director of the Center for Personalized Cancer Therapy at UCSD.
Additionally, Dr. Kurzrock is the founding director of the Michels Rare Cancers Research Laboratories at the MCW Cancer Center.